NCT02853578 - Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2019

Primary Completion Date

October 31, 2020

Study Completion Date

December 31, 2020

Conditions

Asthma

Interventions

DRUG

Busonid (budesonide 200mcg and 400mcg)

"cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;~1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks."

Trial Locations (5)

Unknown

Centro de Estudos Multidisciplinar CEPES da Faculdade de Medicina do ABC, Santo André

Centro de Pesquisa do Hospital Nipo Brasileiro, São Paulo

Centro de Pesquisa em Pneumologia da Santa Casa de São Paulo, São Paulo

Centro Paulista de Investigação Clínica - CEPIC, São Paulo

IMA Brasil - Instituto de Medicina Avançada, São Paulo